B
efore 1980, standard practices for manipulating antineoplastic agents generally involved the use of horizontal-laminar-airflow hoods, with very limited use of personal protective equipment. During the 1980s, anecdotal reports and quantitative studies began appearing that highlighted the potential dangers associated with preparing and administering these medications and the inadequate safety provided by existing practice standards. [1] [2] [3] [4] [5] [6] A series of guidelines and recommendations from professional organizations and government agencies on the safe handling of cytotoxic drugs began appearing. [7] [8] [9] [10] [11] Key elements of today's standards include rigorous training and certification programs; use of class 100 cleanrooms; use of vented class II biological-safety cabinets or barrier isolators; use of appropriate gloves, gowns, caps, and masks; policies for proper storage and disposal; and detailed personnel policies regarding potential teratogenic effects. [12] [13] [14] Despite increased awareness of the potential hazards associated with antineoplastic agents and the resultAbstract: Surface contamination with and personnel exposure to antineoplastic agents before and after the implementation of a closed-system protective device were studied.
Samples were collected before and six months after implementation of PhaSeal, a closed-system device for limiting exposure to antineoplastic agents during preparation and administration. Personnel exposure was evaluated by collecting 24-hour urine samples from pharmacists, pharmacy technicians, and nurses working fulltime in a chemotherapy drug infusion center and pharmacy. Surface contamination was assessed by wiping potentially exposed surfaces. Both types of samples were analyzed for cyclophosphamide and ifosfamide by high-performance liquid chromatography-electrospray ionizationtandem mass spectrometry.
All 17 wipe samples collected before implementation of PhaSeal had detectable levels of cyclophosphamide, and 11 were positive for ifosfamide. Six months after system implementation, 7 of 21 wipe samples had detectable levels of cyclophosphamide and 15 were positive for ifosfamide. Of eight employees who provided urine samples, six were positive for cyclophosphamide and two for ifosfamide before implementation, and none were positive for either drug after implementation.
The PhaSeal system appeared to reduce exposure of health care personnel to cyclophosphamide and ifosfamide. Closed-system protective device plastic medications may vaporize under normal working conditions of temperature and pressure, creating an exposure risk. 24, 25 The National Institute for Occupational Safety and Health is completing a hazardous drug alert entitled "Occupational Exposures to Hazardous Drugs in Health Care Settings," 26 the release of which is expected to result in reviews of current guidelines and standards by such organizations as the American Society of Health-System Pharmacists and the Occupational Safety and Health Administration. While this is occurring, many practitioners are exploring the efficacy of new systems for preparing and administering antineoplastic agents.
PhaSeal (Carmel Pharma, Möln-dal, Sweden; distributed by Baxa Corp., Englewood, CO), a closed, double-membrane system for ensuring leak-free transfers of drugs, has been shown to reduce environmental and personnel exposure compared with existing processes for the preparation and administration of antineoplastics. [27] [28] [29] The system has four basic components:
1. An infusion adapter, the connection between the i.v. bag and a dedicated i.v. set. The adapter and set have a built-in connector to allow for sealed transfer of the medication to the bag. 2. A connector Luer-Lock, providing for a sealed connection between the injector and the i.v. administration set. 3. An injector Luer-Lock, an encapsulated, specially cut cannula that is permanently attached to a syringe and allows for sealed transfer of the medication by means of a double elastomeric membrane. 4. A protector unit, a pressure-equalizing device that permanently attaches to the medication vial and prevents overpressure and vacuum.
At present, the system cannot be deployed for use with ampuls, and some vials are too small or large to accommodate the protector unit.
We wanted to test the PhaSeal system within our institution. Although chemotherapy drugs are prepared at several locations in the hospital, we selected as our study site an ambulatory chemotherapy infusion center and pharmacy located within a specialty cancer research and treatment facility that opened in November 2000. Currently, the infusion center serves approximately 60 patients daily. The pharmacy prepares approximately 15,000 doses of antineoplastic drugs annually. The pharmacy is composed of a retail operation and a chemotherapy drug preparation area. This is adjacent to the infusion center, where patients receive their treatment on an ambulatory care basis. The facility has new equipment, and all personnel are certified in the preparation of antineoplastic drugs by our hospital training program.
The purpose of this study was to assess surface contamination with and personnel exposure to antineoplastic agents before and after implementation of the PhaSeal system at our hospital.
Methods
The study consisted of evaluation of direct personnel exposure through urine samples and evaluation of surface contamination through wipe samples. Each set of samples was analyzed for cyclophosphamide and ifosfamide concentrations. Samples were collected before implementation (BI) of the PhaSeal system in December 2001 and six months after implementation (AI). Although testing was done only for these two agents, PhaSeal was used for all antineoplastic agents during the sixmonth trial. The only exception to using the PhaSeal system during our study was for the administration of intrathecal medications, which occurred in the physician's office, separate from the sampling areas; intrathecal medications were prepared with the PhaSeal system, however.
The study was approved by our institutional review board.
Study volunteers were recruited from the staff of pharmacists, pharmacy technicians, and nurses working full-time in the pharmacy and the infusion center. Volunteers provided informed consent to participate in the study. Throughout the study, all participants continued to adhere to standard safety precautions in the preparation of antineoplastic agents, including the use of a class II, type A/ B3 biological-safety cabinet a and protective gowns, caps, masks, and latex gloves. Participants provided 24-hour urine samples; each urine void was collected separately, and the date, time, and volume of each sample were recorded. Thirty milliliters of each urine sample was sent for analysis. All urine collections were performed toward the end of the workweek, when, theoretically, employee exposure would be highest.
Wipe samples were collected from four areas of the infusion center and the pharmacy. These four areas included the class 100 cleanroom where drug preparation occurred, the pharmacy area where the orders were processed and checked, the nurses' supply room, and the administration area. The samples were collected by spreading 20 mL of 0.03 M sodium hydroxide solution over the surface to be sampled and wiping with two absorbent tissues. 19 The surface area of each wipe sample was measured, and the maximum surface area collected from was 0.5 m 2 . Several samples were taken from each of the four areas. The samples were collected from identical locations BI and AI. Four additional wipe samples were collected AI to examine potential sources of exposure of pharmacy employees who were not involved in the drug preparation but who had detectable levels of antineoplastics in their first set of urine samples. BI, wipe samples were collected one month prior to the collection of the urine samples. AI, both wipe and Closed-system protective device urine samples were collected and tested within the same week. Immediately BI, all surface areas were washed with a cationic soap solution, followed by a diluted bleach solution, followed again by a cationic soap solution and a final alcohol wipe.
Two days of onsite training in the PhaSeal system and one week of practice with the system occurred before the trial. Participants in the study were asked to record any spills or leaks of antineoplastic drugs while using the system during the trial.
Analysis of samples. All samples were analyzed at the toxicology center in our health sciences center by using an adaptation of the techniques of Sottani et al. 30 Samples and working solutions were stored at -20 °C before analysis. The solutions were allowed to come to room temperature (25 °C), portions were removed, and the solutions were returned to -20 °C.
Calibrators and quality-control samples. Stock solutions containing cyclophosphamide b and ifosfamide c (100 ng/µL) used for the preparation of the calibration samples and qualitycontrol samples were prepared in methanol d and stored at -20 °C. The stock solutions were used to prepare working solutions at cyclophosphamide and ifosfamide concentrations of 10, 1, 0.1, and 0.01 ng/µL. The working solutions were used to prepare daily calibration curves and quality-control samples. Calibration curves were obtained by analyzing drug-free human urine fortified with cyclophosphamide and ifosfamide at 0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25, 50, and 100 ng/mL (n = 2 for each concentration). Quality-control samples (0.1, 0.5, 5, and 50 ng/mL) were prepared from stock solutions made from a separate weighing of reference material.
Preparation and extraction of samples. Wipe samples. Collection cups containing the absorbent wipes were prepared for analysis as follows. Ten milliliters of methanol was added to the collection cup, which was capped and shaken for 30 minutes. 
(HPLC-ESI-MS-MS).
Urine samples. The ESI source was operated with a spray voltage of 4.5 kV, sheath gas (high-purity nitrogen gas) at 60 psi, and 10 units of auxilliary gas (highpurity nitrogen gas). The heated capillary was maintained at 250 °C. Positive-ion precursors for cyclophosphamide (m/z 261), ifosfamide (m/z 261), and [ Quantitative analysis. Concentrations of cyclophosphamide and ifosfamide in the wipe and urine samples were determined by calculating peak area ratios for the product ions of each analyte and the internal standard ([ 2 H]PCP). Linear-curve fits were used to ensure accurate quantitation across the dynamic concentration range of the assay (0.1-100 ng/ mL). Quantitation software l was used to generate calibration curves and to calculate cyclophosphamide and ifosfamide concentrations in analyzed samples. Analyte concentrations in the wipe samples were estimated by using the urine calibration curve.
Results
The results for the wipe samples are presented in Table 1 . Seventeen samples were taken BI and 21 AI. Before the PhaSeal system was implemented, all 17 wipe samples had detectable levels of cyclophosphamide; 5 of these had a cyclophosphamide value above the linear range of the assay. These 5 samples came from the air-intake vent of the biological-safety cabinet, the lid of the rigid plastic waste container in the nurses' supply room, the floor in front of that waste container, a patient chair in the drug administration area, and the passthrough door between the cleanroom and the pharmacy area. Eleven
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Closed-system protective device of the 17 samples had detectable levels of ifosfamide. The air-intake vent of the biological-safety cabinet yielded the only sample with an ifosfamide concentration above the linear range of the assay.
AI, 14 wipe samples had undetectable cyclophosphamide concentrations and 7 wipe samples had detectable levels. Of the 7 samples with detectable cyclophosphamide levels, none had a concentration above the range of the assay. All 16 wipe samples that were taken from the same location BI and AI had lower cyclophosphamide levels after the six months.
AI, 6 wipe samples had undetectable ifosfamide levels, and 15 wipe samples had detectable levels. Five of these 15 samples had a level that was above the range of the assay. These five samples were collected from the lid of the plastic waste container, an unopened cyclophosphamide vial, a prepared cyclophosphamide syringe, a patient chair, and the pass-through door. The last ifosfamide order was processed five weeks before the second set of wipe samples was collected.
Two 24-hour urine samples were provided by each of eight employees, including two pharmacists involved in entering and checking chemotherapy drug orders, two nurses involved in administration, two pharmacy technicians working in the pharmacy, one pharmacy technician preparing the chemotherapy doses, and one control subject. Table 2 gives the results for the urine samples. A total of 52 individual urine samples were collected from the eight participants BI. Of these samples, 10 had detectable levels of ifosfamide. One sample belonged to a technician who worked in the pharmacy but did not prepare chemotherapy drugs. The other 9 samples belonged to a pharmacist who was involved in order entry and checking. The last ifosfamide order was processed three weeks before these urine collections.
Eighteen urine samples had detectable levels of cyclophosphamide. One nurse had a positive sample, a second nurse had three positive samples, one pharmacy technician had eight positive samples, and each pharmacist had three positive samples. Fifty-four urine samples were collected from the same eight participants AI. All samples were below the a Before implementation of the PhaSeal system. b Six months after implementation of the PhaSeal system. c ND = not detectable (below the lower limit of detection of the assay [range of assay, 0.1-100 ng]). d Value greater than the range of the test. e Wipe sample was not collected. Closed-system protective device limits of detection for cyclophosphamide and ifosfamide.
Discussion
The PhaSeal system appeared to reduce employee exposure to and surface contamination with cyclophosphamide and ifosfamide. One limitation of this study is that it was descriptive. A control group was not practical because of the small number of staff working in the chemotherapy infusion center and pharmacy and the expense of the analytical methods. The clinical implications of the levels of personnel exposure are unknown. Nonetheless, it is unsettling for any detectable levels of chemotherapy drugs to be present in the workplace environment. While the PhaSeal system appeared to reduce surface contamination and employee exposure, it was used in conjunction with established protective mechanisms (biological-safety cabinet, gown, and gloves). The study also did not assess vaporization of these drugs during preparation.
For the first urine collection, three employees did not have detectable levels of cyclophosphamide and ifosfamide in any of their samples. These three employees included a control worker who did not work in the infusion center or pharmacy, a pharmacy technician who worked in the pharmacy, and a technician who was always fully gowned, gloved, and masked when handling chemotherapy drugs. The five employees who had detectable levels could have been exposed in numerous ways, including handling vials or touching previously contaminated surfaces. During the first urine-collection period, 13 orders accounting for 15.4 g of cyclophosphamide were prepared. During the second urine-collection period, 14 orders accounting for 16.8 g of cyclophosphamide were prepared; however, cyclophosphamide was not detectable in all samples. Ifosfamide had last been prepared three weeks prior to the first urine collections, yet two personnel had detectable levels of that agent. The second set of wipe samples revealed an increase in surface contamination with ifosfamide, yet the last ifosfamide order was prepared five weeks previously. Although surface contamination decreased for cyclophosphamide but increased for ifosfamide, both agents were not detectable in the second set of urine samples.
We have since revised our policies and procedures for handling antineoplastic agents. We are investigating more segregated storage locations throughout our pharmacies and wearing gloves when handling any chemotherapy agents, including when checking stock, handling packaging, and checking prepared products. We are also implementing the PhaSeal system in all locations within our institution involved in the preparation and handling of chemotherapy drugs.
Two recent studies support our findings. In the first study, fluorescein dye was used to examine spillage during chemotherapy drug preparation with and without PhaSeal. 31 The second study looked at both surface contamination and airborne emission. 32 Both studies found that contamination was reduced with the PhaSeal system. Two other studies also used urine concentrations to assess personnel exposure when handling antineoplastic drugs. 33, 34 The clinical implications of detectable urine levels of these agents are unknown.
Unlike a biological-safety cabinet, which represents a one-time capital expenditure that can be depreciated, PhaSeal creates an added annual expense. Depending on configuration and order volume, this system may add $6-$15 to the cost of each chemotherapy drug infusion. During this study, we purchased the PhaSeal system at a price negotiated by our group purchasing organization. We estimate that the system would add approximately $300,000 in annual Table 2 . Closed-system protective device expenses if deployed fully across our entire hospital system. It is possible to add the cost of the system to the cost of the chemotherapy drug infusion; however, reimbursement will vary according to payer mix. With our existing payer mix, we are recovering approximately 50% of our expenditures on this product. Medicare is considering classifying this system as a reimbursable device, but this is typically a slow process. Our most compelling reason for implementing the PhaSeal system was our ethical responsibility to safeguard our employees. Our study demonstrated a potential health risk, as well as identified a tool that appears to reduce that risk. The staff, after seeing our study results, expressed concern about the potential exposure and interest in the system's potential to minimize it.
Results for Urine Samples
Before beginning this study, we consulted the hospital's attorneys. Our concerns centered on what legal risk we would generate if we demonstrated that we were exposing our employees to measurable levels of cytotoxic agents. The legal staff responded that, since we were adhering to accepted standards of practice, our risk would be no greater than that in any other health care organization. However, the lawyers said, if we demonstrated a problem and a potential solution and chose not to pursue that solution, our liability could increase. Although no direct causal relationship between cytotoxic exposure in the workplace and adverse sequelae has been established, the possibility remains. We have chosen to minimize that exposure and liability risk to the greatest degree possible.
The PhaSeal system will not be effective if poor technique is used during the preparation and the administration of antineoplastic agents. The system should be employed in conjunction with current recommendations, such as using biological-safety cabinets, class 100 cleanrooms, and gloves, gowns, caps, and masks.
Conclusion
The PhaSeal system appeared to reduce surface contamination with and exposure of health care personnel to cyclophosphamide and ifosfamide. 
